Cytex’s intellectual portfolio is further strengthened with the most recent US patent continuation, “Tissue Engineering Methods and Composition,” Patent No.: US 9,649,409 B2 on May 16, 2017.
Cytex is excited to receive a Phase 2 STTR award from NIH to fund a project “Unicondylar Resurfacing in Ovine Osteoarthritis”. This study examines the efficacy of Cytex’s cartilage resurfacing implant in an ovine knee model.
Dr. Willard was invited to speak at the 2017 Orthopaedic Research Society annual meeting February 19, 2017. Dr. Willard presented the results of a study entitled “The Mechano and Osmosensitive Ion Channel TRPV4 and How it Serves as a Functional Regulator of iPSC Chondrogenesis.”
Cytex is proud to have Dr. Farsh Guilak preside over the 2017 meeting of the Orthopaedic Research Society in San Diego on March 19th through 22nd, 2017. In addition to serving as president of Cytex Therapeutics, Dr. Farsh Guilak is Professor of Orthopaedic Research and the Co-Director of Regenerative Medicine at Washington University, and one of […]
An image from Cytex’s research on its proprietary implant was featured on the December 2016 cover of Bonezone, an Orthoworld publication focused on commercialization solutions for the orthopedic industry.
Cytex’s 3-D weave technology is featured as this fall’s cover image on the Regenerative Medicine issue of Breakthroughs in Bioscience, a journal highlighting scientific breakthroughs important to society. The publication is produced by Federation of American Societies for Experimental Biology (FASEB), the nation’s largest coalition of biomedical researchers.
Cytex is thrilled to receive an award from NIH to fund strategic regulatory and manufacturing planning to accelerate the commercialization of its products. The grant awarded is part of the pilot Commercialization Readiness Program offered to recipients of NIH Phase II SBIR/STTR awards.
Cytex is delighted to be awarded entry to the highly successful Commercialization Acceleration Program offered as a competitive award to recipients of NIH Phase II SBIR or STTR awards. The program provides training and support for Cytex staff in commercialization activities such as regulatory planning, investment negotiations, and product marketing.
Cytex adds the most recent US patent granted, “Tissue Engineering Methods and Composition,” Division 2006287306 to its intellectual portfolio September 15, 2016.
Cytex is honored to have an image of its resurfacing scaffold selected for the cover image of the Spring-Summer 2016 edition of Science Editor.